Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for approximately 90% of cases. Patients often present at an advanced stage when treatment options are limited. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been the first-line treatment in this setting for almost a decade. Several subsequent targeted therapies have failed to demonstrate significant improvement in survival. The results of the REFLECT study suggest that lenvatinib, a multikinase inhibitor, may have promised as a first-line treatment in patients with advanced HCC. This article will review the development of lenvatinib and the evidence behind its potential use in patients with advanced HCC.
Original language | English |
---|---|
Pages (from-to) | 2021-2029 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 14 |
Issue number | 20 |
Early online date | 22 May 2018 |
DOIs | |
Publication status | Published - Aug 2018 |
Keywords
- drug development
- hepatocellular carcinoma
- lenvatinib
- multikinase inhibitor
- pharmacokinetics
- REFLECT
- sorafenib
ASJC Scopus subject areas
- Oncology
- Cancer Research